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Management, National School of Public Health, Athens, GreeceA B S T R A C TObjective: This observational study aimed to identify clinical varia-
bles and health system characteristics associated with incomplete
guideline application in drug treatment of patients with chronic heart
failure (HF) across 15 countries. Methods: Three data sets were used:
European Society of Cardiology Heart Failure Registry, Organisation
for Economic Co-operation and Development’s Health System Char-
acteristics Survey, and Organisation for Economic Co-operation and
Development Health Statistics 2013. Patient and country variables
were examined by multilevel, multiple logistic regression. The study
population consisted of ambulatory patients with chronic HF and
reduced ejection fraction. Inappropriateness of prescription of phar-
macological treatments was deﬁned as patients not prescribed at least
one of the two recommended treatments (angiotensin-converting
enzyme inhibitors/angiotensin-receptor blockers and beta-blockers)
or treated with both medications but at suboptimal dosage and in
absence of documented contraindication/intolerance. Results: Of
4605 patients, 1097 (23.8%) received inappropriate drug prescriptions
with a large variation within and across countries, with 18.5% of theee front matter & 2015 Published by Elsevier Inc.
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ndence to: Aldo P. Maggioni, ANMCO Research Centotal variability accounted for by between-country health structure
characteristics. Patient-level characteristics such as having mitral
regurgitation (odds ratio 1.4; 95% conﬁdence interval 1.1–1.7) was
signiﬁcantly associated with inappropriate prescription of recom-
mended drugs, whereas chronic obstructive pulmonary disease (odds
ratio 0.7; 95% conﬁdence interval 0.5–0.9) was associated with more
appropriate prescriptions. Among the country-level variables, incen-
tives or obligation to comply with guidelines increased the probability
of prescription appropriateness. Conclusions: Combining clinical var-
iables with health system characteristics is a promising exercise to
explain the appropriateness of recommended drug prescriptions.
Such an understanding can help decision makers to design more
effective policies to improve adherence to guidelines, improve health
care outcomes, and potentially reduce costs.
Keywords: heart failure, health systems, guidelines.
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Remarkable progress in the prevention and treatment of coronary
artery and other cardiovascular diseases has been made in the
last few decades, contributing to at least 7 years of the 10 yearslife span increase observed in recent years [1]. Despite this, and
most likely as a result of such a success, the burden of heart
failure (HF) in Europe remains very relevant, affecting approx-
imately 2% to 3% of the population, rising to around 10% among
those aged 70 years and older [2]. HF is also a common reason foron behalf of International Society for Pharmacoeconomics and
Cardiorentis, Abbott Vascular, and Bayer, outside the submitted
r, and Novartis, grants from Irbtech, and grants and personal fees
ve indicated that they have no conﬂicts of interest with regard to
ter, Via La Marmora, 34 – 50121 Firenze, Italy.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 9 8 – 1 1 0 4 1099hospital admissions and accounts for around 14% of all cardio-
vascular disease–related hospital admissions in Organisation for
Economic Co-operation and Development (OECD) countries [3].
Survival of patients with chronic HF has improved as well over
the last two decades. Several trials have consistently demon-
strated that medical treatment with blockers of the renin-
angiotensin-aldosterone system and beta-adrenergic blockers
improves survival rates of patients with HF and reduced ejection
fraction (EF) [4–6]. This evidence has now been widely incorpo-
rated in clinical practice guidelines that provide practitioners and
patients with recommendations on optimum care [4–6]. There is
also evidence, however, that guidelines are often adopted too
slowly or are applied partially and inconsistently [7–10].
The structure and organization of the health system is likely
to play an important role in explaining the insufﬁcient applica-
tion of guideline recommendations in drug prescriptions. Health
systems that can provide patients with greater access to high-
quality and evidence-based–driven care, ensuring continuous
monitoring and support, can improve their outcomes [11,12].
This study aimed to identify patients’ clinical characteristics
and health system characteristics potentially associated with
incomplete and inconsistent guideline incorporation and appli-
cation of pharmacological treatment of HF in clinical practice in
European countries independently monitored by both the Euro-
pean Society of Cardiology (ESC) and the OECD.Fig. 1 – Patient disposition. EF, ejection fraction; HF, heart
failure; OECD, Organisation for Economic Co-operation and
Development; pts, patients. (Color version of ﬁgure available
online).Methods
Patient-level data were sourced from the ESC Heart Failure Long-
Term Registry [10], and country-level data were derived from
OECD’s Health System Characteristics Survey [13], the OECD
Health Statistics 2013 Database [3], and European Union Statistics
on Income and Living Conditions [14].
Patient-Level Data
ESC’s Heart Failure Long-Term Registry is a prospective observa-
tional study conducted in 211 cardiology centers across 21 Euro-
pean and Mediterranean countries [10]. Centers were selected by
the participating ESC national cardiology societies. To maximize
representativeness, a predetermined broad spectrum of cardiol-
ogy and/or HF units providing different levels of care were
selected to participate according to the number of inhabitants
in that country. The survey was approved by each local institu-
tional review board according to the rules of each participating
country. No data were collected before detailed information was
provided to the patient and a signed informed consent was
obtained.
From May 2011 to December 2013, a total of 17,901 patients
older than 18 years were enrolled on a “one-day-per-week” basis
for 12 consecutive months. Patients were recruited at presenta-
tion in one of the participating centers and classiﬁed on the basis
of whether their presentation was at an outpatient (patients with
chronic HF) or inpatient (patients with acute/worsening HF)
setting. The registry, still ongoing, collects information on the
diagnostic and therapeutic processes applied for these patients in
each participating country. In addition, the reasons why recom-
mended pharmacological treatments were not prescribed, or
were prescribed in a suboptimal dosage, were requested (see
the ESC-HF questionnaire in Appendix 1 in Supplemental Materi-
als found at http://dx.doi.org/10.1016/j.jval.2015.08.005).
Local audits were planned to check the quality of the collected
data and the consecutiveness of enrolment in a randomized
sample of centers and patients.
For the purpose of this analysis, patients living only in OECD
countries, for which health system characteristics data areavailable, were considered. Patients hospitalized for acute HF
were excluded as well as patients with chronic HF for whom the
EF was not available or was equal to or higher than 40%. This is
because current clinical practice guidelines do not include
evidence-based recommendations for these patients. Patients
enrolled in Sweden were also excluded from the analysis because
the questionnaire used in this country did not include informa-
tion on the reasons for nonprescription or underdosage of
pharmacological recommended treatments. The inclusion/exclu-
sion criteria are further illustrated in Figure 1, which reports the
patient disposition.
Inappropriate prescription of pharmacological treatments rec-
ommended by ESC guidelines [5] was deﬁned as follows:1. Patients not treated at all with at least one of the two recom-
mended treatments (angiotensin-converting enzyme inhibi-
tors/angiotensin-receptor blockers and beta-blockers); or2. Patients treated with both angiotensin-converting enzyme inhib-
itors/angiotensin-receptor blockers and beta-blockers, but with a
suboptimal (o100% of the recommended dosage) dosage; and3. Absence of a documented contraindication or intolerance to
the two recommended classes of drugs.
Twenty-one patient-level variables were selected as the most
suitable for assessing the appropriateness of prescriptions of
drug treatment according to current ESC guidelines. These
variables included demographic characteristics (age and sex),
vital signs and symptoms (systolic blood pressure, heart rate,
New York Heart Association class), etiology of HF, laboratory and
instrumental results (left bundle branch block at electrocardio-
gram, EF, sodium, creatinine), classical cardiac risk factors (body
mass index, diabetes mellitus, hypertension), comorbid condi-
tion, and vascular history (history of stroke, atrial ﬁbrillation,
mitral regurgitation, depression, chronic obstructive pulmonary
disease, chronic kidney dysfunction, peripheral arterial diseases).
Country-Level Data
The OECD Health System Characteristics survey collects infor-
mation on a wide range of health system characteristics includ-
ing private or public insurance coverage of health services
and products; the type of system used to pay providers (such as
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 9 8 – 1 1 0 41100fee-for-service); the extent to which health care is ﬁnanced
through public or private means (e.g., patient direct out-of-
pocket costs for health care), provision of health care, and
governance structures [13].
The OECD Health System Characteristics questionnaire is
completed in each country, and responses are coordinated by
national bodies and authorities such as the Ministry of Health.
The present analysis used responses from the 2012 survey wave.
Fifteen country-level variables relating to 1) patient access to
health care, 2) ﬁnancial and physical resources available for
health care, and 3) the use of quality improvement initiatives
within a health care system were selected for the analysis and
used as “group-level” variables. These variables are described in
the Appendix Table 1 in Supplemental Materials found at http://
dx.doi.org/10.1016/j.jval.2015.08.005 along with their country-
level values. Five variables were used to proxy access to care.
These consisted of the proportion of the population that skipped
a doctor consultation within a country, the average per-capita
out-of-pocket expenditure on medical goods and outpatient care,
the patient payment mode for health care services (free at the
point of care or other), and the annual number of doctor
consultations per capita. Variables used to measure health care
resources comprised the percentage share of total health care
resources devoted to ambulatory care, the number of generalist
doctors per 1000 population, and variables related to how the
primary care system is organized. These health system features
were characterized by three dichotomous variables to indicate
whether generalist doctors within a country were primarily
privately (including self) employed (or not); whether (or not)
generalist doctors were primarily paid on a fee-for-service basis;
and whether there were incentives or obligations in a country for
patients to register with a general practitioner. Finally, the
variables related to the quality of care reﬂect whether there are
formal requirements (such as accreditation) for primary care
practices or facilities to operate; there are formal systems in
place for continuous medical education of physicians; patient
information is stored and exchanged across providers; and there
are incentives or obligations for physicians to comply with
treatment guidelines or practice protocols.
OECD Health and Eurostat Statistics
Some quantitative national-level variables were drawn from the
OECD Health Statistics 2013 Database [3]. This data set offers the
most comprehensive source of comparable statistics on health
and health systems across OECD countries. It includes numerous
data on a wide range of topics such as health resources and
activities as well as health expenditures. In addition, the 2011
wave of European Union Statistics on Income and Living Con-
ditions was used to obtain data on the percentage of people who
reported that they did not visit their doctor in the previous 12
months when they felt they needed health care [14].
Statistical Analysis
The ﬁrst step was aimed at identifying patient-level and country-
level variables that could signiﬁcantly predict appropriate appli-
cation of guidelines. Continuous variables are expressed as
means  SD, and categorical variables are expressed as counts
and percentages. Percentages were based on the known total
number of patients pertaining to the variable analyzed. Each
continuous and categorical variable was then examined for its
univariate association with nonadherence to guidelines using
simple logistic regression. The association between nonadher-
ence to guidelines about drug treatment and each covariate was
calculated using odds ratios (ORs) with 95% conﬁdence intervals
(CIs). Student t test and analysis of variance were used tocompare continuous variables, after veriﬁcation of their normal
distribution with the Kolmogorov-Smirnov test. Categorical var-
iables were compared using the chi-square test or the Fisher
exact test. Statistical signiﬁcance was determined at the two-
sided level (using Wald statistics).
In the second step, given the hierarchical nature of the data
(patients nested within countries), the suitability for a hierarch-
ical model was tested in an empty model with the country
identiﬁer as random intercept. All patient-level variables were
then included in the model. Thereafter, group-level covariates
were added and examined at the same time with the clinical
variables.
We used the approximate intraclass correlation coefﬁcient by
Snijders and Bosker [15] to estimate the variability in appropri-
ateness of prescription between countries; this coefﬁcient repre-
sents the proportion of variability explained by the presence of
clusters in the observed population.
The data were analyzed using the SAS, version 9.3, for
Windows statistical software (SAS institute, Cary, NC).Results
Of the initial 17,901 patients consecutively included in ESC’s
Heart Failure Long-Term Registry, 4605 from 15 countries were
ultimately retained for the analysis of prescription appropriate-
ness in ambulatory patients with chronic HF and reduced EF
(Fig. 1). A total of 1097 (23.8%) patients received an inappropriate
prescription, 217 (4.7%) were not prescribed with at least one of
the two recommended treatments, and 880 (19.1%) received a
prescription at a suboptimal dose. Table 1 presents the associa-
tion between patients’ characteristics and rates of inappropriate
prescriptions, estimated by univariate models. Inappropriate
prescriptions were more likely to be given to older patients, with
an EF between 30% and 40%, in New York Heart Association class
I or II and with mitral regurgitation. In addition, inappropriate
prescriptions were less likely observed in patients with chronic
obstructive pulmonary disease. In the univariate analysis, coun-
try health structure characteristics were signiﬁcant predictors of
inappropriate prescriptions. There are statistically signiﬁcant
differences in the average out-of-pocket expenditure and the
share of health expenditure on ambulatory care between appro-
priate and inappropriate prescriptions. Resource, payment, and
quality variables had strong associations with appropriate appli-
cation of guidelines as well as higher numbers of general
practitioners per 1000 population. Countries where general prac-
titioners were mainly privately employed or paid on a fee-for-
service basis also had higher levels of appropriateness. Countries
with no formal requirements for accreditation of primary care
practices, or without a patient registration system, or electronic
exchange of information and no incentives to comply with
guidelines or practice protocols had higher levels of inappropriate
prescriptions.
The multilevel, multiple logistic regression results are sum-
marized in Table 2. To test the suitability of a multilevel model,
the intraclass correlation coefﬁcient was ﬁrst examined in the
empty multilevel model, which included only the identiﬁers for
patients and countries without any predictor variable. It shows
that 18.5% of the total variability is due to variation between
country health structure characteristics.
Having established the signiﬁcance of the characteristics of
the country of residence, patient-level characteristics were added
to the analysis (model 1). The results suggest that having mitral
regurgitation (OR 1.4; 95% CI 1.1–1.6) signiﬁcantly increases the
probability of inappropriate prescriptions while having a chronic
obstructive pulmonary disease (OR 0.7; 95% CI 0.5–0.9) signiﬁ-
cantly decreased this probability.
Table 1 – Characteristics of the study population and inappropriate prescriptions estimated by
univariate models
Characteristic n (%) OR 95% CI P value
Appropriate
prescription
Inappropriate
prescription
(n ¼ 3508) (n ¼ 1097)
Patient-level variables
Age (y)
o65 1857 (52.9) 523 (47.7) 1 0.96–1.31 0.001
65–75 1008 (28.7) 318 (29.0) 1.12 1.19–1.68
475 643 (18.3) 256 (23.3) 1.41
Men vs. women 2752 (78.5) 844 (76.9) 0.92 0.78–1.08 0.31
Body mass index (kg/m2)
o22 327 (9.3) 91 (8.4) 1 0.89–1.55 0.50
22–25 695 (19.9) 228 (20.9) 1.18 0.87–1.43
425 2475 (70.8) 770 (70.7) 1.12
EF o30% vs. Z30% 2001 (57.0) 570 (52.0) 0.81 0.71–0.93 0.04
NYHA class III or IV vs. class II 962 (27.4) 269 (24.5) 0.86 0.73–1.00 0.06
Heart rate 470 bpm vs. r70 bpm 1577 (45.0) 486 (44.3) 0.97 0.85–1.12 0.73
SBP (mmHg)
o110 1227 (35.0) 365 (33.3) 1 0.89–1.23 0.37
110–130 1399 (39.9) 435 (39.6) 1.05 0.95–1.35
4130 881 (25.1) 297 (27.1) 1.13
Creatinine 41.5 mg/dl vs. r1.5 mg/dl 644 (19.6) 216 (21.2) 1.1 0.93–1.31 0.28
Sodium o136 mEq/l vs. Z136 mEq/l 367 (11.6) 121 (12.5) 1.09 0.87–1.36 0.48
Ischemic etiology vs. nonischemic etiology 1664 (47.4) 558 (50.9) 1.15 1.00–1.31 0.05
Atrial ﬁbrillation vs. no atrial ﬁbrillation 1186 (33.8) 378 (34.5) 1.03 0.89–1.19 0.72
Left bundle branch block vs. other ECG morphologies 733 (23.0) 234 (24.9) 1.11 0.94–1.32 0.23
Mitral regurgitation vs. no mitral regurgitation 1032 (29.9) 368 (34.9) 1.26 1.09–1.45 0.003
COPD vs. no COPD 560 (16.0) 145 (12.9) 0.78 0.64–0.95 0.01
PAD vs. no PAD 412 (11.8) 144 (13.2) 1.14 0.93–1.39 0.24
CKD vs. no CKD 638 (18.3) 221 (20.4) 0.96 0.81–1.13 0.14
Diabetes mellitus vs. no diabetes 1174 (33.5) 378 (34.5) 1.05 0.91–1.21 0.57
Prior stroke vs. no prior stroke 322 (9.2) 107 (9.8) 1.07 0.85–1.35 0.60
Depression vs. no depression 266 (7.6) 69 (6.3) 0.82 0.62–1.08 0.17
Country-level variables
Access
Percentage of population skipping a doctor consultation,
mean  SD
6.3  3.2 6.9  3.2 1.14 1.02–1.19 o0.0001
Patient sample living in countries where health services are
primarily free at the point of care
1874 (55.0) 613 (56.8) 1.10 0.94–1.22 0.29
Out-of-pocket expenditures on medical goods (per capita
US $ ppp), mean  SD
213  37 210  31 1.03 1.02–1.04 0.04
Out-of-pocket expenditures on outpatient care (per capita
US $ ppp), mean  SD
215  100 230  104 1.02 1.01–1.04 o0.0001
Number of annual doctor consultations (per capita),
mean  SD
7.4  2.2 7.3  2.0 0.99 0.94–1.00 0.02
Resources
Percentage of share in total health expenditure spend on
ambulatory care, mean  SD
24.5  7.8 23.0  6.8 1.02 1.01–1.04 o0.0001
Number of GPs (per 1000 population), mean  SD 0.9  0.5 0.8  0.4 0.63 0.51–0.74 o0.0001
Patient sample living in countries where GPs are mostly
privately employed
975 (33.4) 261 (27.2) 0.84 0.69–0.97 0.00
Patient sample living in countries where GPs are primarily
paid on a fee-for-service basis
305 (11.7) 60 (6.5) 0.55 0.41–0.78 o0.0001
Patient sample living in countries where there are obligation
or incentives to register with a GP
2981 (89.5) 928 (89.2) 1.04 0.84–1.21 0.81
Quality
Patient sample living in countries where there are formal
accreditation requirements for primary care practices to
operate
2357 (70.8) 688 (66.2) 0.82 0.73–0.94 0.01
Patient sample living in countries with formal system of
continuous medical education
2900 (87.1) 907 (87.2) 1.04 0.82–1.34 0.90
continued
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Table 1 – continued
Characteristic n (%) OR 95% CI P value
Appropriate
prescription
Inappropriate
prescription
(n ¼ 3508) (n ¼ 1097)
Patient sample living in countries with use of a patient
registration system
3171 (95.2) 964 (92.7) 0.64 0.52–0.91 0.001
Patient sample living in countries with electronic exchange of
information between providers
2381 (71.5) 694 (66.7) 0.83 0.74–0.91 o0.001
Patient sample living in countries with incentives to comply
with treatment guidelines
2851 (88.4) 847 (83.2) 0.74 0.49–0.79 o0.0001
CI, conﬁdence interval; CKD, chronic kidney dysfunction; COPD, chronic obstructive pulmonary disease; ECG, electrocardiogram; EF, ejection
fraction; GP, general practitioner; NYHA, New York Heart Association; OR, odds ratio; PAD, peripheral arterial diseases; SBP, systolic blood
pressure.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 9 8 – 1 1 0 41102No signiﬁcant contribution was found for country-level vari-
ables, except for the variable related to incentives to implement
drug treatment guidelines (model 2), although this was only of
borderline signiﬁcance. This observation suggests that incentives
or obligation to comply with treatment guidelines may decrease
the probability of having inappropriate prescriptions.
The description of the variability in the appropriateness of
prescriptions between and within countries is limited by the
small number of patients in some countries, which restricts our
ability to explore speciﬁc country-level data. Just as an explor-
atory analysis, the Appendix Figure in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2015.08.005 shows the
median level of inappropriateness within each country as well
as the range of inappropriate prescriptions. The variability of
inappropriateness across all centers was relatively high, partic-
ularly Denmark, Poland, and the Slovak Republic, where within-
country inappropriateness ranged from 0% to 100% (Appendix
Figure, Panel A). These extreme values were mostly reported by
centers with small patient samples. Panel B shows the within-
country variability when small centers, with fewer than 10
patients, were excluded from the analysis. This restriction
reduced the within-country variation in countries such as Den-
mark and Poland. As shown in Panel B of the Appendix Figure,
centers in Portugal and Slovenia report the lowest levels of
guideline nonadherence, with median levels of 9.5% and 9.9%,
respectively. Within-country variations were also low in Portugal
and Denmark, with interquartile ranges of less than 5 percentage
points for centers with at least 10 patients. Conversely, variability
was relatively high, with interquartile ranges of more than 40% in
the Czech Republic and Israel.Discussion
Our study shows a signiﬁcant country variation in appropriate-
ness of prescriptions of guideline recommendations for patients
with chronic HF and reduced EF. Across OECD countries, 23.8% of
the patients were not prescribed according to the guideline
recommendations. Previous studies have reported higher rates
of nonadherence to guidelines, but these studies did not account
for the reason behind the nonprescription of drugs or of sub-
optimal dosages [16,17]. Lack of this information exposes to
classify as inappropriate the nonprescription of contraindicated
drugs or intolerance of drugs at target doses recommended by the
current guidelines. We have taken in consideration these aspects,
as we deﬁned as inappropriate only the prescriptions to patients
without speciﬁc contraindications or intolerance to each speciﬁc
medical treatment. The detailed list of reasons for not prescribingaccording to recommended treatments for chronic HF and
reduced EF have been reported elsewhere [10]. It follows that
several of the most relevant reasons for nonapplication of guide-
line recommendations were a priori considered and might
explain our relatively low rate of inappropriateness.
Nevertheless, the results reported here are in line with a
previous European study that showed that nonprescription of
recommended treatments ranged between 12% and 64% depend-
ing on pharmacological intervention [17].
Our data show that a large number of patient characteristics
can inﬂuence the level of prescription appropriateness [10,17]. It
is noteworthy that medications are more appropriately pre-
scribed for severe patients with comorbidities than those given
to patients with less severe HF. This attitude, however, should be
corrected because many trials have shown that medical therapy
should be applied as soon as possible to reduce progression
versus more advanced phases [18–20]. An exception was patients
with mitral regurgitation, for whom the prescriptions were less
appropriate than for patients without this functional valve
abnormality.
The novelty of this study is related to the fact that we
explored and tried to integrate clinical patterns with a number
of national health characteristics to help understand whether
different health systems could help explain variations in guide-
line application. A number of these variables were found to be
signiﬁcant in the univariate analysis. Overall, there is a fairly
consistent and logical pattern that indicates that countries with
greater access, a more structured primary care system, better
resourcing, and operative quality programs have better levels of
appropriateness than do countries without these characteristics.
In the full multivariate model, however, our study showed only a
weak evidence of impact of better prescription appropriateness
for one important health system characteristic, that is, to provide
incentives to comply with guidelines.
These considerations are relevant because better appropriate-
ness of prescriptions to recommended guidelines can play a vital
role in reducing health care use and costs and increasing
efﬁciency. Globally, HF imposes a huge economic burden, esti-
mated at $108 billion per annum. With an aging, rapidly expand-
ing, and industrializing global population, this value could
continue to rise [21]. Given the poor prognosis for many patients
and the high health care costs associated with hospital read-
missions, even small improvements in HF care can have a
substantial impact on patients’ quality of life and health care
cost [22].
This exploratory analysis focused on the speciﬁc variations
across countries and found that within-country variations were
higher than cross-country variations. The variability within a
Table 2 – ORs by the multilevel logistic model
Characteristic OR 95%
CI
Model 0. Empty model
Model 1. Controlled for patient-level characteristics
Age (y)
o65 Ref
65–75 1.1 0.9–1.3
475 1.2 0.9–1.5
Men vs. women 0.9 0.7–1.1
Body mass index (kg/m2)
o22 0.9 0.6–1.2
22–25 Ref
425 0.9 0.7–1.1
EF o30% vs. Z30% 0.9 0.7–1.0
NYHA III or IV vs. class II 0.8 0.7–1.0
Heart rate 470 bpm vs. r70 bpm 1.1 0.9–1.3
SBP (mmHg)
o110 0.9 0.7–1.1
110–130 Ref
4130 1.0 0.8–1.2
Creatinine 41.5 mg/dl vs. r1.5 mg/dl 1.2 0.9–1.6
Sodium o136 mEq/l vs. Z136 mEq/l 1.2 0.9–1.6
Ischemic etiology vs. nonischemic etiology 1.2 1.0–1.4
Atrial ﬁbrillation vs. no atrial ﬁbrillation 1.1 0.9–1.3
Left bundle branch block vs. other ECG
morphologies
1.2 1.0–1.5
Mitral regurgitation vs. no mitral
regurgitation
1.4 1.1–1.6
COPD vs. no COPD 0.7 0.5–0.9
PAD vs. no PAD 1.1 0.9–1.5
CKD vs. no CKD 0.9 0.7–1.2
Diabetes mellitus vs. no diabetes 1.1 0.9–1.3
Prior stroke vs. no prior stroke 1.2 0.9–1.6
Depression vs. no depression 0.8 0.6–1.2
Model 2. Controlled for patient-level characteristics and country-
level characteristics
Age (y)
o65 Ref
65–75 1.0 0.8–1.3
475 1.2 0.9–1.5
Men vs. women 0.9 0.7–1.2
Body mass index (kg/m2)
o22 0.9 0.6–1.2
22–25 Ref
425 0.9 0.7–1.1
EF o30% vs. Z30% 0.9 0.7–1.1
NYHA III or IV vs. class II 0.9 0.7–1.1
Heart rate 470 bpm vs. r70 bpm 1.1 0.9–1.3
SBP (mmHg)
o110 0.9 0.7–1.1
110–130 Ref
4130 1.0 0.8–1.3
Creatinine 41.5 mg/dl vs. r1.5 mg/dl 1.1 0.8–1.5
Sodium o136 mEq/l vs. Z136 mEq/l 1.2 0.9–1.6
Ischemic etiology vs. nonischemic etiology 1.2 1.0–1.4
Atrial ﬁbrillation vs. no atrial ﬁbrillation 1.1 0.9–1.4
Left bundle branch block vs. other ECG
morphologies
1.2 1.0–1.6
Mitral regurgitation vs. no mitral
regurgitation
1.4 1.1–1.7
COPD vs. no COPD 0.7 0.5–0.9
PAD vs. no PAD 1.1 0.8–1.5
CKD vs. no CKD 0.9 0.7–1.2
continued
Table 2 – continued
Characteristic OR 95%
CI
Diabetes mellitus vs. no diabetes 1.1 0.9–1.3
Prior stroke vs. no prior stroke 1.2 0.9–1.7
Depression vs. no depression 0.9 0.6–1.2
Incentives to comply with treatment
guidelines
0.4 0.2–1.1
Note. The estimated variance of the random center intercepts on
the logit scale is estimated as 0.7542 (standard error ¼ 0.3255) for
model 0, 0.6356 (standard error ¼ 0.2965) for model 1, and 0.3555
(standard error ¼ 0.2006) for model 2.
CI, conﬁdence interval; CKD, chronic kidney dysfunction; COPD,
chronic obstructive pulmonary disease; ECG, electrocardiogram;
EF, ejection fraction; NYHA, New York Heart Association; OR, odd
ratio; PAD, peripheral arterial diseases; SBP, systolic blood
pressure.
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centers and enrolled patients. Even when comparing countries
with large sample sizes, however, considerable differences
remained. Both within- and across-country variations have
important implications for patients. Patients of some countries,
for example, were more likely to receive appropriate prescrip-
tions, and their choice of center was less important in deﬁning
the likelihood of being correctly prescribed compared with any
other country. In other countries, overall appropriateness could
be high but the likelihood of being treated according to the
guideline recommendations greatly depended on the choice of
the treating center. Good overall guideline application but with
high within-country variation suggests that a more targeted
approach to improve access and quality of care in certain
countries may be beneﬁcial. However, poor overall prescription
appropriateness may warrant more comprehensive measures.Study Limitations
First, the analysis is limited by the small number of patients in
some countries, which restricts our ability to explore country-
level data. Second, despite the methodological desirability of
consecutive enrolment, this cannot be fully proven in the sample
of ambulatory patients with chronic HF. In the attempt to get the
registry burden feasible and realistic, the enrolment was done on
a “one-day-per-week” basis. Local audits were performed to
check quality of data and consecutiveness of enrolment. Third,
although representativeness is a frequent limitation of observa-
tional studies, the centers in the registry sample were selected in
proportion to the size of the population of the participating
countries as well as taking into account the different technolog-
ical levels of the cardiology centers. Fourth, the patients were
enrolled through cardiology clinics, and therefore the study
population may not be representative of the entire chronic HF
population. Fifth, the health system characteristics survey repre-
sents a very high level overview of a health system’s institutional
features and may obscure many internal differences within a
health system. Sixth, some relevant variables in determining
adherence of doctors to guidelines are not available, such as
clinical knowledge to guidelines. Furthermore, the availability
and the accessibility of recommended drugs for HF in the differ-
ent countries were not part of the OECD questionnaire. The lack
of this information is surely a limitation in the interpretation of
the results. Seventh, the analysis of appropriateness of prescrip-
tion is focused just on drug treatments and not on diagnostic
procedures or nonpharmacological therapeutic strategies. Eighth,
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 9 8 – 1 1 0 41104in a relevant number of patients (16%), EF was not measured and
these patients were excluded from the analysis. This can be
considered an inappropriate way to manage patients with HF,
which merits future speciﬁc evaluations. Notwithstanding these
limitations, this analysis has shown the value of combining
individual-level clinical data with national health system data
to undertake cross-country analysis.Conclusions
Despite the lack of a clear statistical signiﬁcance, this analysis
suggests that national health structure characteristics could help
explain some of the variations in the treatment patterns, and it
also points to the importance of within-country variation. Coun-
tries with an easier access to medical care, a more structured
primary care system, better resourcing, and quality programs
have greater levels of appropriateness of prescription of drug
treatment for HF than do countries without these characteristics.
The lack of appropriateness of prescriptions to guidelines
recommendations could have adverse effects on patient out-
comes as well as higher health care costs mainly through
potential preventable hospital admissions. More efforts should
be made toward understanding the role of health system char-
acteristics and policies in explaining the application of guidelines
both within and between countries. Such an understanding can
aid decision makers to design more effective policies to improve
the quality of health care and patients’ outcomes as well as
potentially reduce costs.
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